U.S. stock futures were mixed this morning, with the Dow futures gaining around 150 points on Friday.

Shares of Truist Financial Corporation (NYSE:TFC) fell in pre-market trading following mixed quarterly results.

Truist Financial reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.11 per share. The company reported quarterly sales of $5.304 billion which missed the analyst consensus estimate of $5.354 billion.

Truist Financial shares dipped 2.5% to $45.39 in pre-market trading.

Here are some other stocks moving lower in pre-market trading.

• Telkom Indonesia (Persero) Tbk PT -ADR (NYSE:TLK) shares dipped 14.4% to $10.94 in pre-market trading.
• Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE:LOMA) fell 8.6% to $9.25 in pre-market trading.
• Omeros Corporation (NASDAQ:OMER) declined 6.6% to $17.55 in pre-market trading after the company received CHMP negative opinion following re-examination of European Marketing Authorization application for Narsoplimab in TA-TMA.
• Aclaris Therapeutics Inc (NASDAQ:ACRS) fell 4.6% to $3.33 in pre-market trading.
• CoreWeave Inc (NASDAQ:CRWV) shares dipped 4.1% to $66.82 in pre-market trading after gaining 6% on Thursday.
• Caris Life Sciences Inc (NASDAQ:CAI) fell 3.6% to $30.61 in pre-market trading. Caris Life Sciences will report third quarter financial results on Nov. 4.
• Aclaris Therapeutics Inc (NASDAQ:ACRS) shares declined 3.5% to $3.37 in pre-market trading after gaining 3% on Thursday.
• SK Hynix Inc – ADR (NASDAQ:SKHY) fell 3.1% to $141.52 in pre-market trading. SK hynix stock remained under pressure on Thursday as investors weigh a broader memory-chip selloff, rising Chinese competition, tight NAND supply and concerns about the sustainability of AI infrastructure spending.
• Regions Financial Corp (NYSE:RF) declined 2% to $26.78 in pre-market trading following third-quarter results.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.